ChronoScale Holdings Corporation (CHRN)
| Market Cap | 2.97B +29,096.2% |
| Revenue (ttm) | 71.60M -15.1% |
| Net Income | -50.43M |
| EPS | -0.36 |
| Shares Out | 145.64M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 118,473 |
| Open | 20.17 |
| Previous Close | 20.13 |
| Day's Range | 19.50 - 20.69 |
| 52-Week Range | 3.50 - 30.00 |
| Beta | 0.99 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 19, 2026 |
About CHRN
ChronoScale Holdings Corporation designs and develops a compute platform to support artificial intelligence (AI) workloads in the United States. The company focuses on large-scale deployments and provides dedicated compute environments engineered for performance, consistency, and long-term operational execution. It also provides graphics processing units; computing solutions; AI; machine learning; and high-performance computing solutions. It serves artificial intelligence and machine learning developers. The company was formerly known as Chrono... [Read more]
Financial Performance
Financial StatementsNews
ChronoScale Announces AI Infrastructure Partnership with Microsoft for 50 MW AI Compute Deployment in North America
MENLO PARK, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- ChronoScale Corporation (NASDAQ: CHRN), (“ChronoScale” or the “Company”), an accelerated compute platform purpose-built to support demanding artif...
Nutanix and ChronoScale Announce Strategic Partnership to Accelerate Enterprise AI Adoption
Nutanix and ChronoScale plan to integrate their platforms so enterprises can extend into ChronoScale GPU-as-a-Service, pre-paid inference tokens through ChronoScale Token Factory, and a locally-deploy...
ChronoScale Holdings Registration statement: Registration filing
ChronoScale Holdings filed a registration statement on July 10, 2026, providing details about a securities offering with the SEC.
ChronoScale Holdings Registration statement: Registration filing
ChronoScale Holdings filed a registration statement on June 30, 2026, providing details about a securities offering with the SEC.
ChronoScale Appoints Raj Jegannathan as Chief Technology Officer and Lawrence Lam as Chief Product Officer to Accelerate Global AI Infrastructure Strategy
DALLAS, June 04, 2026 (GLOBE NEWSWIRE) -- ChronoScale Corporation (NASDAQ: CHRN) (“ChronoScale” or the “Company”), an accelerated compute platform purpose-built to support demanding artificial intelli...
ChronoScale Appoints Cenly Chen as Chief Executive Officer to Lead Next Phase of AI Compute Growth
DALLAS, May 06, 2026 (GLOBE NEWSWIRE) -- ChronoScale Corporation (NASDAQ: CHRN), an accelerated compute platform purpose-built to support demanding artificial intelligence workloads, today announced t...
Ekso Bionics Prices $5.852 million Private Placement
SAN RAFAEL, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (the “Company”) (Nasdaq: EKSO), a leading developer of exoskeletons for medical and industrial use, today announced th...
Applied Digital to Spin Out Cloud Business, Proposes Business Combination with EKSO to Launch ChronoScale
DALLAS, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Applied Digital (NASDAQ: APLD), a designer, builder, and operator of high-performance, sustainably engineered data centers and colocation services for artific...
Ekso Bionics Inks Agreement to Become the Exclusive U.S. Distributor of MediTouch's Groundbreaking BalanceTutor™ Rehabilitation System
SAN RAFAEL, Calif. and TNUVOT, Israel, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for ...
Ekso Bionics Announces $3.7 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules
SAN RAFAEL, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (the “Company”) (Nasdaq: EKSO), a leading developer of exoskeletons for medical and industrial use, today announced th...
Ekso Bionics Reports Third Quarter 2025 Financial Results
SAN RAFAEL, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and industr...
Ekso Bionics Reports Second Quarter 2025 Financial Results
SAN RAFAEL, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and industr...
Ekso Bionics to Report Second Quarter 2025 Financial Results on July 28 – Conference Call to Follow
SAN RAFAEL, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today ann...
Virtual eksoUniversity to Support Continuing Education of PTs and PTAs Across the Country
SAN RAFAEL, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and industr...
Ekso Bionics' Acceptance into NVIDIA Connect Program Bears Early Fruit
AI voice agent for user interface being designed to support exoskeleton device operation, motivation, training, and safety First proof-of-concept demonstration comes just over a month after Company an...
Ekso Bionics Announces New Effective Date of Reverse Stock Split
SAN RAFAEL, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (the “Company”) (Nasdaq: EKSO), a leading developer of exoskeletons for medical and industrial use, today announced tha...
Ekso Bionics Announces Reverse Stock Split
SAN RAFAEL, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (the “Company”) (Nasdaq: EKSO), a leading developer of exoskeletons for medical and industrial use, today announced tha...
Ekso Bionics Accepted into NVIDIA Connect Program
Company unveils a strategic initiative to build the world's first known foundation model for human motion in physical rehabilitation
Ekso Bionics Reports First Quarter 2025 Financial Results
SAN RAFAEL, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and industri...
Ekso Bionics to Report First Quarter 2025 Financial Results on May 5 – Conference Call to Follow
SAN RAFAEL, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today an...
Bionic P&O Chosen as First Distributor of Ekso Indego® Personal Within the Orthotics & Prosthetics Industry
SAN RAFAEL, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today an...
Ekso Bionics Reports Fourth Quarter and Full-Year 2024 Financial Results
SAN RAFAEL, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and indust...
Ekso Bionics to Report Fourth Quarter and Full Year 2024 Financial Results on March 3 – Conference Call to Follow
SAN RAFAEL, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today ann...
NSM Named Exclusive Distributor of Ekso Indego® Personal Within the CRT Industry
Move expected to broaden access to Ekso Bionics' portable exoskeleton device for individuals living with spinal cord injuries and other mobility challenges across the United States Move expected to br...
Ekso Bionics to Showcase Its Device Technology in ‘AI for Good' Webinar on Tuesday, November 19
SAN RAFAEL, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today ann...